Decoupling Registration Holder and Distributor in Argentina
Updated: 2026-11-12 · GRZAN Regulatory Team · Verification date 2026-10-20
1. Key takeaways
Under the Argentine framework (per Disposición ANMAT 2319/2002), the registration is held by the local importer as the applicant, and the foreign manufacturer cannot hold the certificate directly; although certificate transfer exists as a procedure, it requires the cooperation of the original holder and takes a practical estimate of about 1–2 months. Consequently, if the license holder and the distributor are one and the same entity, any change in the commercial relationship places the manufacturer’s registration, import rights, and official communication channel under that entity’s control simultaneously.
The solution is to decouple regulatory holding from commercial distribution: agree separately with 3 roles (registration holder, importer, distributor), and choose an independent, stable, professional local entity to hold the certificate long term. Distribution channels can then be changed while the registration stays untouched. This is precisely why a growing number of companies expanding abroad choose a self-operated or third-party independent license holder — the cost of the structure is trivial compared with the leverage it removes from a single counterparty.
2. Legal basis
| Regulation | Reference number | Publication date | Relevant provisions |
|---|---|---|---|
| Operating authorization for manufacturing/importing establishments | Disposición ANMAT 2319/2002 (T.O. 2004) | 2002 (2004 consolidated text) | Applicant eligibility provisions; transfer fee item provisions |
| MERCOSUR technical regulation for medical device registration | GMC/RES 25/21 | October 13, 2021 | Part III, Article 6 (manufacturer authorization declaration) |
| Principal product registration regulation | Disposición ANMAT 64/2025 | Published January 13, 2025 in the Official Gazette | Registration holder provisions |
| Good technovigilance practices | Disposición ANMAT 8194/2023 | Published October 3, 2023, effective October 4, 2023 | Holder vigilance obligation provisions |
3. Expert insights
Insight 1: Argentine regulation requires only that the holder be a qualified local company; it does not require the holder to perform distribution. The regulation itself does not force the binding — commercial convenience created it. Since the regulation leaves this room, companies can avoid the risk entirely at the architecture-design stage. Nothing in the framework obliges the applicant to be the same company that sells the product, which means the decoupled structure is not a workaround but the straightforward use of what the rules already permit.
Insight 2: Vigilance obligations further strengthen the value of independent holding. Disposición 8194/2023 places the vigilance reporting obligation on the registration holder. Where the holder is also the distributor, its attention and capabilities tend to lean toward sales rather than running the vigilance system; an independent license holder can instead industrialize vigilance, change management, and renewal as standardized services. The division of labor also clarifies accountability when an adverse event must be reported: the entity whose legal duty it is performs it, without commercial conflicts pulling in the other direction.
Insight 3: The commercial flexibility gained by decoupling is quantifiable. When a distributor is changed, only the commercial agreement needs adjustment — the registration, import rights, and the ARGOS account do not migrate. By contrast, changing distributors under a bound structure involves certificate transfer, re-notarized authorization, a 1–2 month window, and additional fees. Comparing the two paths line by line converts an abstract governance argument into a cost figure that finance can approve.
4. Practical recommendations
- Distinguish the three roles at the architecture-design stage. Agree separately with the registration holder (titular), the importer (importador), and the distributor (distribuidor); do not let any single entity default into all three functions.
- Prioritize an independent holding entity. Where capability allows, establish a self-operated local entity; where it does not, choose a third-party professional license holder and avoid having the distributor hold the certificate.
- State in the distribution agreement that the certificate does not follow the business. Write expressly that a change of distributor does not affect the ownership of the registration, and that the distributor must cooperate with any necessary document updates.
- Put vigilance and compliance operations into the holder’s service scope. Specify that ARGOS reporting, change filings, and renewal handling are the holder’s responsibility, with agreed response time limits.
5. Verification checklist
- □ The three roles — holder, importer, distributor — are distinguished
- □ The holding entity confirmed not to be bound to distribution interests
- □ The distribution agreement states that the certificate does not follow the business
- □ Responsible entities and time limits for vigilance, changes, and renewal agreed in the agreements
- □ Feasibility of a self-operated local entity or third-party independent holding assessed
- □ A contingency plan for changing distributors prepared (not involving certificate transfer)
Regulatory information verified as of October 29, 2026.
The legal anchors for the decoupled structure are worth keeping visible in negotiations. Disposición 2319/2002 (T.O. 2004) defines who may apply and what the transfer procedure costs; GMC/RES 25/21 Part III, Article 6 defines the manufacturer authorization declaration on which the certificate rests; Disposición 64/2025 restates the registration holder provisions; and Disposición 8194/2023 fixes the vigilance duty on the holder. None of these instruments requires the holder to sell. When a distributor resists a decoupled structure, the conversation should therefore be conducted on commercial terms — pricing, territory, exclusivity of the channel — rather than on regulatory terms, because the regulatory framework offers no support for the claim that the distributor must hold the certificate. Framing it this way usually resolves the resistance faster than any legal argument.
In Argentina, GRZAN operates a wholly-owned subsidiary that can serve as the registration holder and importer for foreign manufacturers, directly handling classification determination, pathway selection, GMP and CFS documentation chains, Spanish-language technical documentation and label localization, HELENA submissions and deficiency responses, as well as BONITA import notifications, ARGOS vigilance system operation, change maintenance, and 5-year renewal planning.
The GRZAN regulatory team consists of professionals with many years of hands-on international registration experience and tracks the dynamics of regulatory authorities across countries on an ongoing basis. All external content follows the drafting standard of conclusions first, traceable bases, and verifiable figures. For an Argentina or MERCOSUR market access plan tailored to a specific product, contact the GRZAN regulatory team at info@grzanglobal.com.
Disclaimer
Prepared by GRZAN from publicly available regulation. It is provided for general information only and does not constitute legal advice. Legislation and official fees are subject to change by the competent authority.
About GRZAN
GRZAN (Global Regulatory Zone Access Navigator) — the global market-access navigator for medical devices and IVDs.
GRZAN is a specialist consultancy for medical device and IVD market access, providing end-to-end regulatory solutions across the product lifecycle and making international market entry simpler and faster.
Key figures. More than 25 wholly owned subsidiaries worldwide covering 50+ countries and regions; chosen by 100+ listed and leading Chinese device manufacturers, with 4,000+ successful cases; 12+ years in the sector and 200+ regulatory training sessions and seminars delivered.
What we do. Global market access: multi-country registration programmes, technical documentation, regulatory advice. Clinical evidence: clinical evaluation reports (CER), usability studies, overseas clinical investigations. Quality systems: ISO 13485, MDSAP, FDA QMSR and BGMP implementation and audit readiness. Authorised representative and licence-holder services across Southeast Asia, Latin America, the Middle East, Africa, Europe and North America.
Why GRZAN. A real operating entity, with the certificate held by the manufacturer: our direct overseas subsidiaries act as the compliant local holder, so the regulatory relationship stays clear and you keep control rather than being tied to a distributor. Direct access to the team: no time-zone gap, no language barrier, no cultural gap. Review points anticipated: we know what FDA 510(k), EU MDR, Southeast Asian, Latin American and Middle Eastern reviewers look for, which shortens timelines and reduces deficiency letters. Pathway planning: pre-decision analysis and risk assessment before you commit.
Every engagement rests on three commitments: efficiency through pre-submission review, certainty through a clear pathway, and stability through a licence-holder that stays in place.
Take your devices global with GRZAN
We work with manufacturers worldwide to open new markets with a clear regulatory pathway.
Contact us